KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene-Reference-Cited by-同舟云学术

KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

Published:2020-06-18 Issue:1 Volume:22 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Roberts Melyssa S.,Anstine Lindsey J.,Finke Viviane S.,Bryson Benjamin L.,Webb Bryan M.,Weber-Bonk Kristen L.,Seachrist Darcie D.,Majmudar Parth R.,Keri Ruth A.^ORCID

Funder

National Institutes of Health

National Cancer Institute

U.S. Department of Defense

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-020-01305-7.pdf

Reference60 articles.

1. Schmid P, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21. https://doi.org/10.1056/NEJMoa1809615 .

2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721–8. https://doi.org/10.1002/cncr.22618 .

3. Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502. https://doi.org/10.1001/jama.295.21.2492 .